Croissy-Beaubourg and Montpellier, January 15, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announces that it has renewed the Standby Equity Facility (SEF®) arranged with Société Générale, as approved by the shareholders’ annual meeting of April 8, 2014.

Michel Finance, Chief Executive Officer of Theradiag, comments: “We have used the entirety of the previous SEF® set up with Société Générale. Its proceeds have allowed us to prepare the international development of our LISA TRACKER portfolio, while limiting any dilution for our shareholders. We have decided to renew this SEF®, to further support our international activities and bring to market new theranostics tests, all while preserving our financial structure thanks to a limited discount”.     

Under the terms of the new SEF®, Société Générale has committed to subscribe to successive capital increases, issued by tranches over the next 24 months, within the global limit of 500,000 shares, i.e. 9.64% of the number of shares currently outstanding[1].

For each tranche, the issuance price will reflect the volume-weighted average price of shares for the three trading days immediately preceding the issue date, minus a discount of no more than 5%. This discount will enable Société Générale to instantly underwrite the shares despite possible market volatility. Acting as financial intermediary, Société Générale has no intention to remain a shareholder of the Company.

Should the entire standby equity facility be drawn down[2], a shareholder currently owning 1.0% of the company’s share capital would see his or her share ownership reduced to 0.91%[3].


[1] 5,185,449 shares currently outstanding

[2] Leading to the issuance of 500,000 new shares

[3] Based on the non-fully diluted number of shares currently outstanding

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 60 employees.

 

For more information about Theradiag, please visit our website: www.theradiag.com

Theradiag

Investor Relations

Nathalie Trepo

+33 1 64 62 10 12

ntrepo@theradiag.com

 

 NewCap

Financial communications / investor relations

Valentine Brouchot /

Pierre Laurent

+33 1 44 71 94 94

theradiag@newcap.fr

 

Alize RP

Press

Caroline Carmagnol /

Valentine Boivin

+ 33 6 83 48 23 27

theradiag@alizerp.com